Jim's Articles

Leading vaccine company born from Profectus Biotech and Medisun Medical Group new joint venture

The famous American vaccine company Profectus settled in Hong Kong

First recommend HPV cervical cancer treatment vaccine

BALTIMORE, MARYLAND, USA and HONG KONG, April 20, 2018

Profectus Biotech and Medisun Medical Group today announced the opening of a new joint venture in Hong Kong. The primary mission of the new company, ProMed BioSciences, Ltd., is to establish a leading vaccine company focused on the development of preventive and therapeutic vaccines for infectious diseases and cancer. The joint venture will leverage Profectus’ vaccine development expertise, clinically proven vaccine platform technology and a developing vaccine product line, in line with Medisun’s expertise, established clinical network and market access capabilities, expected in the second half of 2018 to put into operation.

The company’s first product development program will focus on the development, production and commercial application of prophylactic and therapeutic vaccines for HPV (human papillomavirus)-related lesions and cervical cancer [based on PBSVax® technology developed by Profectus]. ProMed BioSciences also plans to develop and treat hepatitis C virus (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Chikungunya and Zika, as well as personalized vaccines to treat cancer. The joint venture is expected to launch new vaccines in their respective markets, which will help promote the development of new vaccines, but ultimately the goal is to benefit patients around the world.

Mr. Jeffery Meshulam (first from left), President of Profectus Biotechnology, Mr. Terry Lierman (second from left), Chairman of Medivh Medical Group, and Mr. Danny Wong (fourth from right), founder and executive chairman of Medisun Medical Group, at Profectus ,USA.

– Long-term strategic cooperation to address the huge demand for prevention and treatment of infectious diseases and cancer in Asia

-Profectus’ expertise in vaccine development and platform technology, combined with Medisun’s localized expertise and experience, to establish a leading Hong Kong vaccine company focused on serving Asia

“This strategic cooperation will help establish Profectus’ business in Hong Kong and China. Through close cooperation with Medisun, we can assist Hong Kong and China to develop advanced vaccine technology to help prevent and treat Asian patients. Mr. Jeffrey Meshulam, President of Profectus, said, “We are pleased to be able to work with recognized local partners to achieve the highest standards of scientific research and development integration and medical services.”

“This collaboration will help Profectus and Medisun to jointly produce life-saving vaccines for infectious diseases and cancer, and address the huge medical needs that have not been met in Hong Kong, China and Asia.” Mr. Danny Wong, founder and executive chairman of Medisun Medical Group, said “ProMed BioSciences will leverage Profectus’ expertise in vaccine development and technology, combined with Medisun’s local expertise and close links with healthcare facilities in Hong Kong and China, and government medical regulatory agencies to develop vaccines to provide leadership for Asian patients disease prevention and treatment programs.”

ProMed BioSciences will focus on the following:

• Conduct technical research in Hong Kong or China

• Conduct clinical trials in Hong Kong or China

• Promote the expansion of Medisun Medical Center

• Develop vaccines to address disease prevention needs

• leverage to maximize the expertise of both partners

Mr. Jeffery Meshulam, President of Profectus Biotechnology (first from left), Mr. Terry Lierman, Chairman of Medisun Medical Group (first from right), Mr. Danny Wong, founder and executive chairman of Medisun Medical Group (middle), at the US headquarters of  Profectus.

About ProMed BioSciences

ProMed BioSciences Limited is a joint venture between Profectus BioSciences (USA) and Medisun Medical Group (Hong Kong) in Hong Kong to develop and conduct new vaccine clinical trials and commercial applications to address infectious diseases and cancer in Asia with the huge demand for prevention and treatment.

About Medisun

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as quality hospitals and treatment centers. Medisun invests extensively in the fields of regenerative and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun and Harvard University Stem Cell Research Institute, Johns Hopkins Medical School Life Science Center, Tsinghua University and other institutions have long-term cooperation plans to jointly invest in regenerative and stem cell therapy technology, with Medisun as a cooperative business The holding entity and holds global intellectual property rights. Medisun and the University of Maryland’s Institute of Human Virology (IHV) set up a technology clinical trial and development platform for viruses and cancer. Based on the Medisun Biomedical Laboratory in Hong Kong, Radiation will jointly build medical clinics in China and Asia. The experimental resource network promotes the world’s largest clinical research and development platform for virus research and cancer treatment technology. The Medisun Reproductive Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments.

For more information, please visit http://www.medisun.hk/

About Profectus BioSciences

Profectus BioSciences is a clinical stage vaccine development company focused on developing new vaccines for infectious disease and cancer prevention and treatment. The Profectus vaccine is based primarily on the company’s proprietary VesiculoVax™ and DNA vaccine technology platform. By simply using the VesiculoVax™ vaccine alone, B cells can be rapidly expanded to provide protection against emerging infectious diseases that threaten public health and biodefense mechanisms, such as Ebola, Marburg, Chikungunya, Zika virus, equine encephalitis virus, and respiratory syncytial virus. When VesiculoVax™ is used as a vaccine when the immune system is launched with the best pDNA vaccine, the Vesiculo Vax™-directed vaccine expands the triggered T cells into effector cells, which are ideal for attacking virus-infected cells and cancer. Current projects using the Prime / Boost Vaccine System (PBS Vax™) strategy include hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus ( HIV). Partners and collaborators include UTMB’s Galveston National Laboratory, Yale University, University of Maryland Human Virology Institute, HIV/AIDS Vaccine Immunology Center, National Cancer Institute, National Institutes of Health AIDS Division, Bill And the Melinda Gates Foundation, the International AIDS Vaccine Initiative, the AIDS Vaccine Trial Network and the AIDS Clinical Trial Group. Profectus is funded by Cross Atlantic Capital Partners (“XACP”) in Radnor, Pennsylvania. The main investor in XACP is the Pennsylvania Public School Employees Retirement System (“PSERS”). For more information, please visit www.profectusbiosciences.com

England and Cornwall Tours

Body and Minds Spirit Journeys presents : Three British Isles Tours for you to choose

Scotland, England and Ireland are rich with some of the most magical places of Mother Earth. Now, Body Mind Spirit Journeys invites you to experience three sacred sites tours next Spring.

Scotland: May 14 23, 2018

Tarot Magic in the Wild Scottish Highland and Islands will be a journey of exploration through the mists of time.

Here are some highlights:

Prehistoric Clava Cairns and standing stones
– The Fairy Glen of Rosemarkie
– Loch Ness, home of the legendary Nessie monster
– Skara Brae, Maes Howe, the Stones of Stennes and the Ring of Brodgar in the Orkney Islands
– Holy Iona Abbey, Nunnery and St. Columbas Chapel

See the See the Scotland tour details here.

Body Mind Spirit Journeys is a Wholesale Tour Operator, not simply a travel agency

1. By working directly with hosts and tour leaders, we are able to pass along the savings from normal marketing expenses and agency commissions to you and your guests. This allows you to act as our agents, and earn your free trips from the money that would otherwise be paid to the retail agent so no-one is up-charged in your group in order to cover your free trip(s) and expenses.

2. Your itinerary is custom designed for you and exclusive for you and your guests. Youll not be placed into a group of strangers. You can participate as much or as little as you want during the tour you have earned your free trip during the time you promoted it. Once you depart, those who joined you are your guests, and you are there as our guest and partner. Click here to see some sample group tour itineraries.

3. You will be amazed by how many people will want to travel with their spiritual leader and friends of like mind and consciousness. There is simply no other way to share this type of camaraderie, and everyones life will be enlightened by the experience.

More Ireland Tours info :

Body Mind Spirit Journeys
P.O. Box 448
Montauk, NY 11954
USA
BMSJ@bodymindspiritjourneys.com

Body Mind Spirit Journeys is a division of RMC Travel.

The famous American vaccine company Profectus settled in Hong Kong

The famous American vaccine company Profectus settled in Hong Kong

First recommend HPV cervical cancer treatment vaccine

BALTIMORE, MARYLAND, USA and HONG KONG, April 20, 2018

Profectus Biotech and Medisun Medical Group today announced the opening of a new joint venture in Hong Kong. The primary mission of the new company, ProMed BioSciences, Ltd., is to establish a leading vaccine company focused on the development of preventive and therapeutic vaccines for infectious diseases and cancer. The joint venture will leverage Profectus’ vaccine development expertise, clinically proven vaccine platform technology and a developing vaccine product line, in line with Medisun’s expertise, established clinical network and market access capabilities, expected in the second half of 2018 to put into operation.

The company’s first product development program will focus on the development, production and commercial application of prophylactic and therapeutic vaccines for HPV (human papillomavirus)-related lesions and cervical cancer [based on PBSVax® technology developed by Profectus]. ProMed BioSciences also plans to develop and treat hepatitis C virus (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Chikungunya and Zika, as well as personalized vaccines to treat cancer. The joint venture is expected to launch new vaccines in their respective markets, which will help promote the development of new vaccines, but ultimately the goal is to benefit patients around the world.

Mr. Jeffery Meshulam (first from left), President of Profectus Biotechnology, Mr. Terry Lierman (second from left), Chairman of Medivh Medical Group, and Mr. Danny Wong (fourth from right), founder and executive chairman of Medisun Medical Group, at Profectus ,USA.

– Long-term strategic cooperation to address the huge demand for prevention and treatment of infectious diseases and cancer in Asia

-Profectus’ expertise in vaccine development and platform technology, combined with Medisun’s localized expertise and experience, to establish a leading Hong Kong vaccine company focused on serving Asia

“This strategic cooperation will help establish Profectus’ business in Hong Kong and China. Through close cooperation with Medisun, we can assist Hong Kong and China to develop advanced vaccine technology to help prevent and treat Asian patients. Mr. Jeffrey Meshulam, President of Profectus, said, “We are pleased to be able to work with recognized local partners to achieve the highest standards of scientific research and development integration and medical services.”

“This collaboration will help Profectus and Medisun to jointly produce life-saving vaccines for infectious diseases and cancer, and address the huge medical needs that have not been met in Hong Kong, China and Asia.” Mr. Danny Wong, founder and executive chairman of Medisun Medical Group, said “ProMed BioSciences will leverage Profectus’ expertise in vaccine development and technology, combined with Medisun’s local expertise and close links with healthcare facilities in Hong Kong and China, and government medical regulatory agencies to develop vaccines to provide leadership for Asian patients disease prevention and treatment programs.”

ProMed BioSciences will focus on the following:

• Conduct technical research in Hong Kong or China

• Conduct clinical trials in Hong Kong or China

• Promote the expansion of Medisun Medical Center

• Develop vaccines to address disease prevention needs

• leverage to maximize the expertise of both partners

Mr. Jeffery Meshulam, President of Profectus Biotechnology (first from left), Mr. Terry Lierman, Chairman of Medisun Medical Group (first from right), Mr. Danny Wong, founder and executive chairman of Medisun Medical Group (middle), at the US headquarters of  Profectus.

About ProMed BioSciences

ProMed BioSciences Limited is a joint venture between Profectus BioSciences (USA) and Medisun Medical Group (Hong Kong) in Hong Kong to develop and conduct new vaccine clinical trials and commercial applications to address infectious diseases and cancer in Asia with the huge demand for prevention and treatment.

About Medisun

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as quality hospitals and treatment centers. Medisun invests extensively in the fields of regenerative and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun and Harvard University Stem Cell Research Institute, Johns Hopkins Medical School Life Science Center, Tsinghua University and other institutions have long-term cooperation plans to jointly invest in regenerative and stem cell therapy technology, with Medisun as a cooperative business The holding entity and holds global intellectual property rights. Medisun and the University of Maryland’s Institute of Human Virology (IHV) set up a technology clinical trial and development platform for viruses and cancer. Based on the Medisun Biomedical Laboratory in Hong Kong, Radiation will jointly build medical clinics in China and Asia. The experimental resource network promotes the world’s largest clinical research and development platform for virus research and cancer treatment technology. The Medisun Reproductive Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments.

For more information, please visit http://www.medisun.hk/

About Profectus BioSciences

Profectus BioSciences is a clinical stage vaccine development company focused on developing new vaccines for infectious disease and cancer prevention and treatment. The Profectus vaccine is based primarily on the company’s proprietary VesiculoVax™ and DNA vaccine technology platform. By simply using the VesiculoVax™ vaccine alone, B cells can be rapidly expanded to provide protection against emerging infectious diseases that threaten public health and biodefense mechanisms, such as Ebola, Marburg, Chikungunya, Zika virus, equine encephalitis virus, and respiratory syncytial virus. When VesiculoVax™ is used as a vaccine when the immune system is launched with the best pDNA vaccine, the Vesiculo Vax™-directed vaccine expands the triggered T cells into effector cells, which are ideal for attacking virus-infected cells and cancer. Current projects using the Prime / Boost Vaccine System (PBS Vax™) strategy include hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus ( HIV). Partners and collaborators include UTMB’s Galveston National Laboratory, Yale University, University of Maryland Human Virology Institute, HIV/AIDS Vaccine Immunology Center, National Cancer Institute, National Institutes of Health AIDS Division, Bill And the Melinda Gates Foundation, the International AIDS Vaccine Initiative, the AIDS Vaccine Trial Network and the AIDS Clinical Trial Group. Profectus is funded by Cross Atlantic Capital Partners (“XACP”) in Radnor, Pennsylvania. The main investor in XACP is the Pennsylvania Public School Employees Retirement System (“PSERS”). For more information, please visit www.profectusbiosciences.com

LeewayHertz ICO launch services

We are an end-to-end ICO launch services provider for all types of cryptocurrency startups. We do a 2-week sprint with you and your team to kickstart development and marketing efforts to go live and start raising funds. In first 2 weeks, our team develops smart contracts for pre-sale and crowd-sale. In parallel, we develop the website, landing page and also make a custom marketing plan to achieve the goals.

We have partnered with top ICO listing sites, forums, PR sites and therefore guarantee to get your ICO maximum visibility and quick traction. Our support team works round the clock to give you top notch service and answer every query that your investors might ask before being involved with your startup.

Examples of our work :

Xchange Apps

XChange is a barter system dApp developed on blockchain. XChange app is one of the biggest and revolutionary ideas in the shared economy on the blockchain platform.

We have completed website, app designs, Smart contracts, Crypto Wallet and Bounty program.

Our ICO Services :

Bounty Program

Our team consists marketing experts who can help you design a well-planned Bounty program. We understand that additional efforts like article writing, bug reporting, and language translation needs external help. We help you create a Bounty program that will get your tasks completed externally. We also provide an admin panel to manage the complete bounty campaign.

Bounty Program Document
Unique Designs
Graphic Assets
Website on Live Environment for admin and bounty seekers

White Paper Drafting

White Paper is the most important document which should be precisely written to explain the Platform. We work as a team on the whitepaper development.

Final Design and layout of the white paper
Detailed White-paper
Light Paper
One Pager
Business Deck

Growth Hack / ICO Marketing Services

Growth hacking is a process of rapid experimentation across marketing channels, and other areas of the business to identify the most efficient ways to grow a community and sales

Digital Strategy
Content Strategy
Influence Marketing
Website Marketing
Campaign Management
Email Marketing
PR & Outreach
Performance Marketing

Contact Details:

Website : https://www.leewayhertz.com/ico-launch-services/
Address:
San Francisco
388 Market Street
Suite 1300
San Francisco, CA 94111
Phone: 877-801-8115
info@leewayhertz.com
jobs@leewayhertz.com

Is Robert Berson the 2018 west coast artist manager to watch ?

Every year there are some music producers that just go “BOOM”. Is 2018 Robert Berson’s year? Judging by the success of his managed artists it could very well be. Just watch him closely because there are a lot of signs pointing to a Robert Berson boom year! You can find out more about him on his website Robert Berson Management.

This Los Angeles based Massachusetts born music producer has played a fundamental part in the creation of many albums, such as: Yellowcards When Youre Through Thinking Say Yes (Acoustic), Ocean Avenue (Acoustic), Punk Goes Rock (Today Cover) and Punk Goes Chritmas (Christmas Lights Cover), Like Torches Keep Your Head High, We The Kings Just Keep Breathing and Find You There, Artist VS Poets among others. With over 20 years of experience in the ever expanding music industry (record production, engineering and song writing), as well as his extensive knowledge of musical equipment used yesterday and today, Robert manages to create the most diverse sound around.

He has worked with the following artists among others: Ryan Key, Cassadee Pope, Travis Clark (We The Kings), Jake Bundrick (Mayday Parade), Sara Mann, BB The Jerk, Rick Thorne, Still Standing, Justin Coppolino, Longineu Parsons II, Dan Lavery (Tonic, The Fray) Tiffany Houghton, Austin Carlile (Of Mice and Men) Tommy Cooperman (it Boys, Breathe Carolina) David Ryan Strauchman (Every Avenue) Liz Hill (Starling Glow), Alex DeLeon (The Cab) Cady Grooves,Nash Overstreet (Hot Chelle Rae), Joe Kirkland (The Voice, AVP) AJ Mclean, Ryan Cabrera, Sean Mackin (Yellowcard), Josh Kelley, Erik Kertes, Paul Doucette (Matchbox Twenty), Jeremy Renner, Edwin McCain, etc. Robert is known for his hard work ethic, positive attitude and respect for the artists vision. Many of his long term work relationships have turned into close friendships.

Robert Berson Management (RB Management) is a talent management company that started by connecting up and coming talent with established professionals. Leveraging Roberts reputation within the music industries he has recently become a full service management company with access to Radio, TV and Film.

Contacts:

Website : http://robertberson.com/
Mailing Address
P.O. Box 691012
Los Angeles, Ca 90069

Twitter: https://twitter.com/robertberson
Instagram: https://www.instagram.com/robertberson/
Facebook: https://www.facebook.com/robert.berson.7

Article About “Property Brothers” Star Raises Thorny Questions

U.S. – March. 26, 2018 – Some people have an eye for detail that eludes others and that’s true of writer and freelance researcher, Amy Katz. Her recent article about Jonathan Silver Scott, one of the stars of the “Property Brothers” HGTV series, raises interesting questions and has been receiving a lot of attention.

Katz’s article centers on Scott and his relationship with girlfriend, Jacinta Kuznetsov, a woman he talks about extensively in his memoir “It Takes Two.” In the book, Scott claims he met Kuznetsov briefly at a charity event, but didn’t get her name or contact information. It supposedly took him a month of scouring social media to discover her identity, despite Kuznetsov walking the red carpet and being tagged in numerous photos.

That’s where some readers have cried foul, saying his account of meeting Kuznetsov in the book is at odds with other accounts he gave to the press. Scott commented on Kuznetsov’s social media account four days after the charity event, which would indicate he did, indeed, know her identity long before he claims.

Kuznetsov was formerly the producer of the Canadian music radio talk show, “The Strombo Show,” featuring George Stroumboulopoulos. The Canadian celebrity is a friend of Scott’s and is supposedly the person who finally identified Kuznetsov in a social media photo.

In another account, Scott related that he maintained contact with Kuznetsov after meeting her at the event, a detail that’s in conflict with his version of events in “It Takes Two.” Yet another description of events indicates it was six months before Scott was able to identify her.

The conflicting stories don’t make sense to fans and Katz. They wonder why it was necessary to imbue the couple’s meeting with so much mystery. It’s just one of the reasons that Katz’s article is gaining so much traction.

Before Scott was the host of “Property Brothers,” he was an award-winning magician and illusionist whose accolades at age 16 included 3rd Best State Performer of the Pacific Coast Association of Magicians. For many, the points made in Katz’s article makes them wonder if Scott was exercising his powers of illusion in regard to his relationship with Kuznetsov, and if so, to what end.